The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Identifying high-risk myeloma: immune aging, inflammation, T-cell reactivity, & arginine metabolism
Erin Meermeier, PhD, Mayo Clinic, Phoenix, AZ, Marta Chesi, PhD, Mayo Clinic, Scottsdale, AZ, Simone Minnie, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, Linda Baughn, PhD, Mayo Clinic, Rochester, MN, share insights from a session on identifying functional high-risk multiple myeloma. Dr Meermeier discusses the role of immune aging in the risk of progression to active disease, and Dr Chesi comments on how an immunocompetent mouse model can be used to test whether inflammation drives tumor growth. Following this, Dr Minnie discusses the challenge of identifying myeloma-reactive T-cells, and Dr Baughn highlights the role of arginine metabolism in t(11;14) myeloma. This discussion took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
